Quick Takeaways: Why It Matters? BiomEdit’s new patents effectively lock up its engineered Lactobacillus reuteri pvAb platform, giving it composition‑of‑matter and methods‑of‑use protection around BE‑101 and future in situ biologic payloads delivered vi...
Quick Takeaways: Why It Matters? BioTesserae’s BTC-001, a PD‑1–targeting single‑domain antibody for canine cancer, showed good tolerability in healthy dogs in a single‑ascending‑dose study, with doses up to three times the anticipated therapeutic level. Ins...
Quick Takeaways: Why It Matters? BE-101’s move into pivotal field safety testing brings the poultry sector closer to a commercially viable, non-antibiotic solution for necrotic enteritis, addressing a major economic and welfare burden while aligning with global pressure to...
